+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oral administration of the specific epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is efficacious against EGFR-overexpressing intracranial tumors



Oral administration of the specific epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is efficacious against EGFR-overexpressing intracranial tumors



Proceedings of the American Association for Cancer Research Annual Meeting 43: 785




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035434405

Download citation: RISBibTeXText


Related references

Brain tumors in children with neurofibromatosis: additional neuropsychological morbidity?. Neuro-Oncology 1(4): 275-281, 1999

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer 40(3): 301-307, 2003

ZD1839 , a selective epidermal growth factor receptor tyrosine kinase inhibitor , enhances the antiproliferative effects of calcitriol in squamous cell carcinoma Effects on ERK and Akt. Proceedings of the American Association for Cancer Research Annual Meeting 43: 783, 2002

A selective biomimetic tweezer for noradrenaline. Journal of the American Chemical Society 125(40): 12086-7, 2003

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Research 62(9): 2554-2560, 2002

Inhibition of proliferation and induction of apoptosis by tanshinone II A in NCI-H460 cell. Zhong Yao Cai 28(4): 301-304, 2005

Antitumor activity of the root of Euphorbia helioscopic in vitro. Zhong Yao Cai 22(2): 85-87, 1999

Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology and Therapeutics 75(2): P32, 2004

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Seminars in Oncology 29(1 Suppl 4): 37-46, 2002

ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat. Pulmonary Pharmacology and Therapeutics 12(5): 303-312, 1999

Epidermal growth factor receptor tyrosine kinase inhibitor , ZD1839 , in combination with 5-fluorouracil and leucovorin , in advanced colorectal cancer. European Journal of Cancer 37(Suppl. 6): S18-S19, 2001

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. Journal of Clinical Oncology 23(28): 6957-6965, 2005

ZD0473 treatment in lung cancer An overview of the clinical trial results. European Journal Of Cancer. 38(supplement 8): S13-S18, Ember, 2002